论文部分内容阅读
Background &Aims:Upper gastrointestinal bleeding (UGIB)is a severe and frequent complication of cirrhosis. Recombinant coagulation factor VIIa (rFVIIa) has been shown to correct the prolonged prothrombin time in patients with cirrhosis and UGIB. This trial aimed to determine efficacy and safety of rFVIIa in cirrhotic patients with variceal and nonvariceal UGIB. Methods: A total of 245 cirrhotic patients (Child Pugh <13; Child Pugh A = 20%, B = 52%, C = 28%) with UGIB (variceal = 66%, nonvariceal = 29%, bleeding source unknown = 5%) were randomized equally to receive 8 doses of 100 μg/kg rFVIIa or placebo in addition to pharmacologic and endoscopic treatment. The primary end point was a composite including: (1) failure to control UGIB within 24 hours after first dose, or (2) failure to prevent rebleeding between 24 hours and day 5, or (3) death within 5 days. Results: Baseline characteristics were similar between rFVIIa and placebo groups. rFVIIa showed no advantage over standard treatment in the whole trial population. Exploratory analyses, however, showed that rFVIIa significantly decreased the number of failures on the composite end point (P = 0.03) and the 24 hour bleeding control end point (P = 0.01) in the subgroup of Child Pugh B and C variceal bleeders. There were no significant differences between rFVIIa and placebo groups in mortality (5 or 42 day) or incidence of adverse events including thromboembolic events. Conclusions: Although no overall effect of rFVIIa was observed, exploratory analyses in Child Pugh B and C cirrhotic patients indicated that administration of rFVIIa significantly decreased the proportion of patients who failed to control variceal bleeding. Dosing with rFVIIa appeared safe. Further studies are needed to verify these findings.
Background & Aims: Upper gastrointestinal bleeding (UGIB) is a severe and frequent complication of cirrhosis. Recombinant coagulation factor VIIa (rFVIIa) has been shown to correct the prolonged prothrombin time in patients with cirrhosis and UGIB. This trial aimed to determine efficacy and safety of Methods: A total of 245 cirrhotic patients with Child Pugh A = 20%, B = 52%, C = 28% with UGIB (variceal = 66%, nonvariceal = 29%, bleeding source unknown = 5%) were randomized equally to receive 8 doses of 100 μg / kg rFVIIa or placebo in addition to pharmacologic and endoscopic treatment. The primary end point was a composite including: (1) failure to control UGIB within 24 hours after first dose, or (2) failure to prevent rebleeding between 24 hours and day 5, or (3) death within 5 days. Results: Baseline characteristics were similar between rFVIIa and placebo groups. rFVIIa showed no advantage over standard treat Exploratory analyzes, however, showed that rFVIIa significantly decreased the number of failures on the composite end point (P = 0.03) and the 24 hour bleeding control end point (P = 0.01) in the subgroup of Child Pugh There were no significant differences between rFVIIa and placebo groups in mortality (5 or 42 days) or incidence of adverse events including thromboembolic events. Conclusions: Although no overall effect of rFVIIa was observed, exploratory analyzes in Child Pugh B and C cirrhotic patients pointed that administration of rFVIIa significantly decreased the proportion of patients who failed to control variceal bleeding. Dosing with rFVIIa was safe. Further studies are needed to verify these findings.